The biotech era in late-stage drug R&D and marketing has arrived. And it looks like it’s here to stay

In a new report out looking over the landscape of drug R&D, IQVIA has been tracking the swelling role that startups play in the development game. And some of the conclusions may surprise you.

First and foremost, the number of active R&D compounds surged 37% in the 5 years from 2013 to 2018. And with biotechs able to operate increasingly independently of Big Pharma partners, the researchers determined that emerging companies now control 72% of the 2,853 late-stage drugs they tracked.